Klec et al. found that ALYREF can promote breast cancer by binding to the Nuclear Enriched Abundant Transcript 1(NEAT1) promoter region, enhancing the overall transcriptional activity of NEAT 1 and stabilizing Cleavage and Polyadenylation Specific Factor 6 [93]. Here, ALYREF is linked to breast carcinoma.